ArticleClinical pharmacology and therapeutics2026
Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo-acute kidney injury. Creatinine-cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients. This single-center prospective observational study included 63 Japanese patients with breast cancer receiving abemaciclib. On-treatment serum creatinine and cystatin C were measured in all patients, with pre-treatment cystatin C available in 29. eGFR was calculated using the Japanese equations (eGFRcre, eGFRcys), and the discrepancy quantified as their difference and ratio. Associations between change in serum creatinine and renal transporter polymorphisms (SLC22A2 rs316019, SLC47A1 rs2289669, and SLC47A2 rs12943590) were evaluated by hierarchical regression. Serum creatinine increased in 62 patients (median change, 0.21 mg/dL) and eGFRcre decreased by a median of 20.5 mL/min/1.73 m
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.